Last reviewed · How we verify

NCT03100422: MultiVIT-ARMin

Strategies of Therapy With the Exoskeleton Robot ARMin

Completed NA Last updated 17 July 2020
What this trial tests

NA trial testing ARMin in Stroke in 18 participants. Completed in 31 October 2018.

Timeline
1 May 2017
Primary endpoint
31 October 2018
31 October 2018

Quick facts

Lead sponsorSwiss Federal Institute of Technology
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment18
Start date1 May 2017
Primary completion31 October 2018
Estimated completion31 October 2018
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Swiss Federal Institute of Technology

Who can join

18 and older, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neurological patients (e.g., after stroke) need long-term neurorehabilitation therapy of the arm with often limited, unsatisfactory outcome. Robots became a promising supplement or even alternative for neurorehabilitation training.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Swiss Federal Institute of Technology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03100422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing